Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Appointed director
Aptevo Therapeutics Inc. (APVO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
05/11/2023 8-K Quarterly results
11/10/2022 8-K Quarterly results
Docs: "Updated Results from a Phase 1study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome” will be presented on Sunday, December 11, 2022 from 6:00 PM-8:00 PM Central time"
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
11/12/2021 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS WITH BUSINESS HIGHLIGHTS"
08/12/2021 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS WITH BUSINESS HIGHLIGHTS"
05/11/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "www.aptevotherapeutics.com"
11/07/2019 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS"
08/09/2019 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS"
05/09/2019 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS"
03/18/2019 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
08/09/2018 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS"
05/10/2018 8-K Quarterly results
Docs: "IXINITY – is a third-generation recombinant human coagulation factor IX approved in the United States for the control and prevention of bleeding episodes and for perioperative management in adults and children 12 years of age or older with Hemophilia B. ADAPTIR Clinical and Preclinical Pipeline: • Otlertuzumab – a monospecific ADAPTIR candidate currently in Phase 2 clinical development for the treatment of peripheral T-cell lymphoma . A previous Phase 2 clinical study evaluating otlertuzumab for the treatment of chronic lymphocytic leukemia showed that otlertuzumab in combination with bendamustine, compared to bendamustine alone, demonstrated a significant increase in median progression free survival for the combination, from approximately 10 to 16 months. • APVO414 – a bispe..."
03/13/2018 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
11/09/2017 8-K Asset disposition, Quarterly results
Docs: "Equity Distribution Agreement, between Aptevo Therapeutics Inc. and Piper Jaffray and Company, LLC",
"APVO414 – a bispecific ADAPTIR candidate, currently in Phase 1 development, targeting prostate specific membrane antigen , an enzyme that is expressed on the surface of prostate cancer cells, and, CD3, a component of the T cell receptor complex expressed on all T cells. APVO414 redirects T cells to specifically kill PSMA expressing tumors and is being developed for metastatic castration-resistant prostate cancer, which is advanced prostate cancer that has spread to other organs and no longer responds to hormone blocking therapies. • Otlertuzumab – a monospecific ADAPTIR candidate currently in Phase 2 development for the treatment of chronic lymphocytic leukemia . Data from a Phase 2 clinical trial evaluating otlertuzumab in combination with bendamustine, compared to bendamustine alo...",
"Presentation of Aptevo Therapeutics dated November 2017"
08/10/2017 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS"
05/12/2017 8-K Form 8-K - Current report
03/31/2017 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy